CLAIMS

1. A pharmaceutically acceptable acid addition salt of:
   (i) S-oxprenolol; and
   (ii) phosphoric acid.

2. A pharmaceutically acceptable acid addition salt according to claim 1, wherein the pharmaceutically acceptable acid addition salt is crystalline.

3. A pharmaceutically acceptable acid addition salt according to claim 1 or claim 2, wherein the pharmaceutically acceptable acid addition salt is S-oxprenolol dihydrogenphosphate.

4. A pharmaceutically acceptable acid addition salt according to any one of the preceding claims, wherein the pharmaceutically acceptable acid addition salt is S-oxprenolol mono-dihydrogenphosphate.

5. A pharmaceutically acceptable acid addition salt according to claim 3 or claim 4, wherein the S-oxprenolol dihydrogenphosphate is in the form of S-oxprenolol dihydrogenphosphate crystalline polymorph Pattern 3 having an x-ray powder diffraction pattern comprising peaks at 4.8°, 7.1° and 8.2° ± 0.2° 2θ.

6. A pharmaceutically acceptable acid addition salt according to claim 5, wherein the x-ray powder diffraction pattern further comprises peaks at 22.5°, 22.7° and 23.2° ± 0.2° 2θ.

7. A pharmaceutically acceptable acid addition salt according to claim 5 or claim 6, wherein the x-ray powder diffraction pattern comprises seven or more peaks selected from 4.8°, 7.1°, 8.2°, 14.2°, 14.4°, 22.5°, 22.7°, 23.2°, 23.5° and 23.8° ± 0.2° 2θ.

8. A pharmaceutically acceptable acid addition salt according to any one of the preceding claims, wherein the pharmaceutically acceptable acid addition salt has a melting point of at least 80°C.

9. A pharmaceutically acceptable acid addition salt according to claim 8, wherein the pharmaceutically acceptable acid addition salt has a melting point of from 85°C to 90°C.

10. A composition comprising at least 60 wt% of a pharmaceutically acceptable acid addition salt as defined in any one of the preceding claims relative to the total weight of the composition.

11. A composition according to claim 10, wherein the composition comprises no more than 30 wt% of R-oxprenolol or a salt thereof relative to the total weight of the composition.

12. A pharmaceutical composition comprising (i) a pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 9 and (ii) a pharmaceutically acceptable excipient, carrier or diluent.

13. A pharmaceutical composition according to claim 12, wherein the enantiomeric excess of the pharmaceutically acceptable acid addition salt in the pharmaceutical composition is at least 90 %, preferably at least 95 %.

14. A pharmaceutical composition according to claim 12 or claim 13, wherein the pharmaceutical composition is a tablet.

15. A pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 9 for use in the treatment of the human or animal body.

16. Use of a pharmaceutically acceptable acid addition salt as defined in any one of claims 1 to 9 in the manufacture of a medicament for the treatment or prevention of a disease or condition selected from cachexia, sarcopenia, a neuromuscular disorder, muscle weakness, hypertension, heart failure, atrial fibrillation, heart attack, angina pectoris, glaucoma and anxiety.

17. Use according to claim 16, wherein the disease or condition is selected from cachexia, a neuromuscular disorder and muscle weakness.

18. Use according to claim 16 or 17, wherein the neuromuscular disorder is amyotrophic lateral sclerosis.